Patient Perspectives in Mantle Cell Lymphoma Clinical Research

Clinical studies with a distinct emphasis on mantle cell lymphoma play a pivotal role in evaluating the safety and effectiveness of novel treatments for this disease. These trials are instrumental in ascertaining whether new medications surpass conventional therapies, providing substantial evidence to endorse their broad utilization.

This particular study stands out as it centers on the firsthand experiences of individuals battling mantle cell lymphoma who are actively engaged in a clinical trial featuring medicinal interventions. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this patient group.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Mantle Cell Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Mantle-Cell Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Location contact

Michael B Gill

CONTACT

https://www.withpower.com/[email protected]

415-900-4227

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Confirmed diagnosis of mantle cell lymphoma
No serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

Concurrent participation in another therapeutic clinical trial.
Subject has an uncontrolled infection
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Treatment and study plan

Primary outcomes

Number of patients who decide to enroll in a mantle cell lymphoma clinical study

Time frame: 3 months
Rate of patients who remain in a mantle cell lymphoma clinical study to trial completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

4159004227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Exploring Patient Engagement Patterns and Participation Trends in Mantle Cell Lymphoma Clinical Trials

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Sep 22, 2023
Registry last updated: Sep 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting